Bringing Retinal Health into focus
Therapeutics for Dry Age-Related Macular Degeneration
Therapeutics for Macular Degeneration and Other Age-Related Disorders»
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues. Our lead indication is Dry Age-Related Macular Degeneration (Dry AMD).
Dry-AMD Overview
Dry-AMD is a progressive disease
Resulting in loss of photoreceptor cells and visual acuity
Patients struggle with everyday tasks
Such as driving, cooking, reading, and facial recognition
11 million people are affected in the US
There are no approved therapies
Age-Related Macular Degeneration and Geographic Atrophy»
We believe dysregulation of lipid (fatty acid) bio-synthesis resulting from declining expression of a gene known as ELOVL2 underlies Dry Macular Degeneration.
